Ruitanning (Fosrolapitant Palonosetron) – CINV | HongKong DengYue Medicine

Fosrolapitant Palonosetron Application Scope

It is used to prevent both acute and delayed nausea and vomiting in adult patients undergoing moderately emetogenic chemotherapy. This combination therapy helps improve patient comfort and adherence to chemotherapy by targeting the key pathways that trigger chemotherapy-induced nausea and vomiting.

Fosrolapitant Palonosetron Characteristics

• Ingredients: Fosrolapitant Palonosetron

• Properties: ​Fosrolapitant is a neurokinin-1 (NK1) receptor antagonist prodrug; Palonosetron is a 5-HT3 receptor antagonist. Together, they effectively prevent chemotherapy-induced nausea and vomiting.

• Packaging Specification:​ 218 mg Fosrolapitant + 0.25 mg Palonosetron per vial, 1 vial per box

• Storage:​ 2–8°C, protect from light

• Expiry Date: See product label

• Executive Standard: ​Complies with national drug standards

• Approval Number: NMPA Z20250001

• Date of Revision: May 27, 2025

• Manufacturer: Fujian Senkeda Pharmaceutical Co., Ltd.

Guidelines for the Use of Ruitanning

• Dosage and Administration:

  • Recommended Dose: 1 vial (218 mg Fosrolapitant + 0.25 mg Palonosetron)

  • Administration: Administer 30 minutes before chemotherapy

  • Missed Dose:​ If a dose is missed, administer as soon as possible following physician guidance

• Adverse Reactions:

  • Common Adverse Reactions:

    • Headache

    • constipation

    • fatigue

  • Serious Adverse Reactions:

    • Allergic reactions

    • QT interval prolongation

      ​

• Contraindications: Hypersensitivity to the drug or its components

• Precautions:

  • Assess cardiac function before using it
  • Especially in patients at risk of QT prolongation
  • Use caution in pregnant or breastfeeding women and consult a physician

Fosrolapitant Palonosetron Interactions

• It may interact with drugs that strongly inhibit or induce CYP3A4 enzymes, which can alter its metabolism.
• Caution is also advised when used with anticoagulants or medications that may affect cardiac function.
• Patients should be closely monitored with ECG and regular blood tests to ensure safety during treatment.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.